In March 1993, Sunty Property Development Co., Ltd. was established. In May, it signed with Japanese Biochemical Industry Co., Ltd. to be an exclusive agency of Yan Jie product in the Republic of China, and with the Swiss Vifor International to be an exclusive agency of chalybeate product in Taiwan. In December 2000, it got the exclusive right for Aimiluo product of Elvis Asia Limited (IVAXASIA LTD) and Likuining product of Yeung Sum (JANSSEN-CILAG Taiwan) in Republic of China. In May 2002, it signed with the Masterlink Securities Corp. OTC to get counseling for listing. In October, it got the exclusive rights for paclitaxel injection (Genetaxyl), PPV and sugar tablet provided by JANSSEN-CILAG Taiwan. In April 2003, it issued public offering. In September, it signed with Jacob Biotech Co., Ltd. to be an exclusive agency of GSP injection in Taiwan. In October 2003, it was allowed to trade as Emerging Stock at GreTai Securities Market. In October 2003, it got the distribution rights for Dimicr-onMR from Singapore Business Servicer Co., Ltd. Taiwan Branch. In November, the company signed with Genovate Biotechnology Co., Ltd. to co-develop LNC drugs. In the same month, it became the general agency of Ya Jie Products for Japanese Biochemical Industry Co., Ltd.
12F, No.289, Sec.4, Zhongxiao E. Rd., Taipei, Taiwan
Taipei City; Taipei City;
Contact Details: Purchase the Sunty Development Co., Ltd. report to view the information.
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.Request a demo of the EMIS service
To view more information, Request a demonstration of the EMIS service